Stroke recovery is one of the most marketed off-label uses of HBOT. The pitch in clinic ads is hopeful. The data behind that pitch is much thinner than the marketing hints.
This page lays out what the trials actually show. The short version up front: early stage, one-site dominant, and not part of any guideline.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | NOT approved for stroke recovery |
| UHMS classification | Not on the 14 approved indications list |
| Medicare coverage | NOT covered for stroke recovery |
| Insurance coverage | Out-of-pocket only at most clinics |
| Typical out-of-pocket | $6,000-$15,000 for a 40- to 60-session course |
| Evidence grade | Low — single research group, no replication |
The evidence
Stroke recovery HBOT has one prominent trial. Most clinic marketing leans on it. Independent replication is missing.
The Efrati and colleagues 2013 PLoS ONE trial, PMID 23308226 enrolled 74 patients 6-36 months post-stroke. The design was a crossover with a delayed-treatment control arm. SPECT imaging suggested gains in dormant brain regions and the authors reported neurologic gains in 43% of patients.
The single-center design has been a sticking point. The control arm was not a true sham. The crossover plan makes blinding hard, and most of the marketing line for stroke HBOT traces back to this one paper.
Boussi-Gross was a co-investigator on the Efrati 2013 stroke paper. The same group published the Boussi-Gross 2013 mild TBI trial, PMID 24260334 using a similar crossover design.
The AHRQ evidence report on HBOT for brain injury, cerebral palsy, and stroke, 2003 reviewed the older stroke trials. AHRQ found no consistent benefit across the available studies at that time.
The McDonagh and colleagues AHRQ-linked review, 2003 also covered the stroke literature. The conclusion was that the evidence did not support HBOT in stroke recovery.
The Bennett and colleagues Cochrane review on acute stroke, 2014, PMID 25387992 looked at acute ischemic stroke. The review found no clear benefit and called for better trials.
A 2019 imaging-based outcomes study from the same Israeli group, PMID 31846850 tried to predict which post-stroke patients respond. The work stayed inside the same research center.
The American Heart Association and American Stroke Association 2019 stroke recovery guidelines do not list HBOT as a recommended therapy for chronic stroke recovery. Standard rehab, speech therapy, and time-bound interventions are listed.
The 2013 PLoS ONE paper is intriguing. It has not been replicated by an independent group. That gap is the single most important fact for patients comparing this against clinic claims.
Why people pursue this anyway
Stroke recovery is hard. Standard rehab plateaus for many patients within 6-12 months. The promise of more recovery years later is emotionally powerful.
A chain called Aviv Clinics built a global marketing push around the Efrati plan. Other wellness chains such as Restore Hyper Wellness and a long tail of small clinics also market HBOT for stroke. Press placements run in major outlets and testimonials drive demand.
The honest gap is that testimonials and one single-center trial are not the same as proof. Patients deserve to know that gap before they pay.
For deeper context on the marketing-vs-evidence split, see our evidence-vs-marketing review of this clinic chain and our analysis of institutional silence on HBOT.
What stroke guidelines actually say
The 2019 American Heart Association and American Stroke Association rehab guidelines do not include HBOT. The European Stroke Organisation also does not list HBOT for chronic stroke recovery.
UHMS does not include stroke on its 14 approved indications list. The official UHMS HBO indications page, 2024 is the source of truth.
Major academic stroke centers do not offer HBOT for chronic stroke recovery. Their wound care and decompression services run for FDA-approved uses only.
The silence from these bodies is not an oversight. It reflects the evidence gap. One unreplicated trial does not change guideline writing.
Cost versus evidence
A 40- to 60-session course at a wellness clinic runs $6,000 to $15,000. Premium chain packages can run higher.
Patients face this cost without insurance support. HSA and FSA accounts may or may not accept the claim, depending on plan rules.
That price stacks against a single unreplicated trial. The math asks a hard question — is one PLoS ONE paper worth a five-figure spend?
The framing is not that no patient should try this. The framing is that the evidence does not justify the marketing-implied confidence.
What to ask your physician
Patients considering HBOT for stroke recovery can ask several questions. Each cuts through the marketing.
What is the FDA approval status for this use — the answer is "not approved." Who has replicated the Efrati 2013 trial — the answer is "no independent group has." What does my neurologist think of the evidence — the answer varies but is usually skeptical.
For chamber-type details, see our hard-shell vs soft-shell chamber explainer. The Efrati protocol uses medical-grade hard chambers from makers such as Sechrist Industries and Perry Baromedical, not the soft chambers found at many wellness centers.
Distinguishing from FDA-approved uses
Stroke recovery sits very differently from approved HBOT uses. The approved list — carbon monoxide poisoning, dive injury, stubborn bone infection, diabetic foot wounds, and ten others — all have decades of backing data.
Our decompression sickness evidence atlas and diabetic foot ulcer evidence atlas show what real FDA-approved HBOT evidence looks like — multiple independent trials, multi-center designs, and a settled mechanism.
Stroke recovery does not have that backing. The honest call is to label it "investigational" and let patients decide with eyes open.
Frequently asked questions
Is HBOT FDA-approved for stroke recovery?
No. The FDA recognizes 14 conditions for HBOT and stroke recovery is not among them. The UHMS approved indications list, current 2024, also does not include stroke recovery.
What does the Efrati 2013 trial actually show?
The trial reported neurologic gains in 43% of post-stroke patients after HBOT. The trial was single-center and used a delayed-treatment control rather than a sham. No independent group has replicated the findings in the years since.
Will Medicare or insurance cover this?
Generally no. Medicare and most commercial plans cover HBOT only for the 14 approved indications. Stroke recovery is out-of-pocket at almost all clinics offering this protocol.
How much does a course cost?
Most wellness clinics charge $250 to $400 per session. A 40- to 60-session course runs $6,000 to $15,000. Premium chain packages are often higher.
What do stroke specialists say?
The American Heart Association and American Stroke Association 2019 rehab guidelines do not list HBOT as a recommended therapy. Most academic stroke centers do not offer this protocol.
Sources
- Efrati and colleagues PLoS ONE 2013, PMID 23308226
- Boussi-Gross and colleagues TBI trial 2013, PMID 24260334
- Bennett Cochrane acute stroke 2014, PMID 25387992
- Imaging-outcomes study 2019, PMID 31846850
- AHRQ Evidence Report on HBOT for Brain Injury, 2003
- McDonagh AHRQ review 2003, PMID 12856236
- AHA/ASA 2019 Stroke Recovery Guidelines
- UHMS HBO Indications List, 2024
Medical disclaimer
This page is medical journalism and not medical advice. HBOT for stroke recovery is an investigational off-label use without FDA approval. Standard stroke rehab including speech, physical, and occupational therapy remains the guideline-recommended path. Talk to your neurologist before pursuing any out-of-pocket HBOT protocol. This page does not diagnose, treat, or substitute for professional medical care.